A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease

BACKGROUND: Ustekinumab was approved for moderate and severe Crohn’s disease (CD) in 2016, but little is known about long-term outcomes. METHODS: A retrospective study evaluated all patients with CD treated with ustekinumab, including patients with reinduction. C-reactive protein (CRP), Harvey-Brads...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Audrey, Evers Carlini, Lauren, Duley, Caroline, Garrett, Ailish, Annis, Kim, Wagnon, Julianne, Dalal, Robin, Scoville, Elizabeth, Beaulieu, Dawn, Schwartz, David, Horst, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067228/
https://www.ncbi.nlm.nih.gov/pubmed/32201860
http://dx.doi.org/10.1093/crocol/otaa013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067228/
https://www.ncbi.nlm.nih.gov/pubmed/32201860
http://dx.doi.org/10.1093/crocol/otaa013

Ejemplares similares